Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lumenato and Its Impact on Skin Parameters in Healthy Female Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04356456
Recruitment Status : Withdrawn (Covid-19)
First Posted : April 22, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
LycoRed Ltd.

Brief Summary:
The purpose of this study is to evaluate perceived changes in skin health and appearance after taking the study product daily for 12 weeks. The study product is a soft gel supplement containing tomato oil. cored Lumenato supplement on skin health and appearance.

Condition or disease Intervention/treatment Phase
Skin Dietary Supplement: Lumenato Not Applicable

Detailed Description:

This is a pilot study, randomized and double-blinded designed to evaluate and compare the efficacy of a once a day dietary supplement to reduce the appearance of wrinkles and uneven skin tone and to diminish the appearance of fine lines and wrinkles, to affect skin complexion and texture and to strengthen the skin barrier, over the course of a 12-week use period, and 2 weeks post usage.

Randomization at 1:1 ratio and is done by the sponsor. The product will arrive blinded (with the kit number stated on the label) neither subjects nor study staff will know the identity of the test products. A sequential number of bottles will be assigned to every enrolled subject.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomization at 1:1 ratio for active or placebo
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Randomized and Double-blinded Study Designed to Evaluate and Compare the Efficacy of a Once a Day Dietary Supplement to Reduce the Appearance of Wrinkles and Uneven Skin Tone and to Diminish the Appearance of Fine Lines and Wrinkles, to Affect Skin Complexion and Texture and to Strengthen the Skin Barrier, Over the Course of a 12-week Use Period, and 2 Weeks Post Usage
Actual Study Start Date : January 14, 2020
Actual Primary Completion Date : June 30, 2020
Actual Study Completion Date : August 8, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lumenato Supplement
Lumenato oleoresin
Dietary Supplement: Lumenato
tomato oleoresin obtained from yellow dry tomato pulp

Placebo Comparator: Placebo
paraffin oil
Dietary Supplement: Lumenato
tomato oleoresin obtained from yellow dry tomato pulp




Primary Outcome Measures :
  1. VISIA-CR® images of each subject's face [ Time Frame: 12 weeks ]
    VISIA-CR® takes a series of standardized, reproducible digital facial images, inside of a controlled lighting environment. Subjects' front, left, and right views will be captured with their eyes gently closed using the following lighting parameters.


Secondary Outcome Measures :
  1. Baseline Skin Questionnaire [ Time Frame: 12 weeks ]
    Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective "Baseline Skin Questionnaire"

  2. End of Study Product Questionnaire" [ Time Frame: 12 weeks ]
    Participant perception of the study product and study experience as assessed by the "End of Study Product Questionnaire"

  3. Skin Update Questionnaire [ Time Frame: 12 weeks ]
    Participant perception of change or maintenance in a variety of skin health parameters over the course of the study using the subjective "Update Skin Questionnaire"


Other Outcome Measures:
  1. Adverse events (AEs) observed during the study, classified by the investigator as to severity, relationship to the study product/protocol, and seriousness [ Time Frame: 14 weeks ]
    classified by the investigator

  2. Compliance to the daily use of the Lycored Lumenato supplement through monitoring within ClaimIt (Weekly e-Diary) [ Time Frame: 12 weeks ]
    Weekly e-Diary



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Resides in the United States
  • Generally healthy women between the ages of 35-55
  • Fitzpatrick skin types 2 or 3
  • Identifies as one of the following: White, Hispanic/Latino, or both White and Hispanic/Latino
  • Type 2 on the Glogau Skin Classification scale
  • Has expressed interest in improving skin health and appearance
  • Willing and able to follow the procedures of the study
  • Willing to refrain from changing their diet or lifestyle significantly for the duration of the study
  • Able to understand the study requirements and activities in English, and provide informed consent
  • Access to reliable internet service and smartphone in order to utilize the ClaimIt software/app needed to remotely participate in the study

Exclusion Criteria:

  • Participants with Fitzpatrick skin types of 1, 4, 5 or 6
  • Known allergies or sensitivity to tomato, latex and/or potato
  • Current use or use within 1 month of study enrollment of hormonal therapies (including hormonal contraceptives)
  • Current, regular use or regular use within 1 month of study enrollment of oral steroids; regular use defined as >10 consecutive days
  • Chronic or relapsing inflammatory and/or allergic skin conditions such as atopic dermatitis, rosacea, psoriasis and alike including telangiectasias ("spider veins")
  • Pregnant, lactating or breastfeeding women (within the last 6 months) or those planning to become pregnant during the study period
  • Less than 2 years since diagnosis or treatment of skin cancer including basal cell carcinoma, squamous cell carcinoma, melanoma- excluding actinic keratosis
  • Currently active herpes infections or currently on treatment for herpes infections
  • History of facial keloids
  • Current diagnosis of adult acne or currently on treatment for adult acne
  • Recent (<6 months at enrollment) cardiovascular conditions such as stroke, transient ischemic attack (TIA), or myocardial ischemia/infarction, recently on treatment for congestive heart failure, or currently having vasculitis or vascular conditions
  • On potent blood thinners such as low-molecular weight heparin (LMWH), rivaroxaban, apixaban, or other prescription blood thinners - excludes aspirin
  • Holds a current diagnosis of diabetes mellitus type I or II
  • Participants who have received facial irradiation within last year or are planning on undergoing facial irradiation during the study
  • Chronic liver disease- excluding early stage non-alcoholic fatty liver disease (NAFLD)
  • Chronic kidney disease or recent (<6 months at enrollment) acute kidney disease
  • Participants who currently take supplements containing carotenoids, lutein, melatonin or tryptophan
  • Participants with occupations or lifestyle that require significant daily exposure to the sun (defined as at least 1 hour of continuous outdoor sun exposure)
  • Participants who have had a sunburn in the last 2 weeks
  • Participants who use tanning salons or tanning products in the last 3 months
  • Participants who plan to undergo invasive facial procedures (injections, chemical peeling, etc.) during the study or have undergone these procedures within 2 months prior to enrollment
  • Change in oral supplements or medications targeting skin health within 2 months prior to enrollment
  • Participants who are HIV positive
  • Participants who are immunosuppressed
  • Participants with a recent (<2 months prior to enrollment) diagnosis of a psychiatric condition
  • Participants having chronic connective tissue disorder affecting the skin (e.g. Ehlers- Danlos syndrome, Marfan's Syndrome, Osteogenesis Imperfecta)
  • Participants with auto-immune skin diseases (e.g. scleroderma, psoriasis, lupus, epidermolysis bullosa, bullous pemphigoid, temporal arteritis)
  • Participants who have been prescribed retinoids treatment (<2 months prior to enrollment)
  • Participants who meet either/or both of the following criteria with regards to smoking habits (smoking includes cigarettes, e-cigs, pipes, hookah, cigars):
  • Who are current smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime) and who continue to use these products
  • Who were former smokers (smoked at least 100 cigarettes, or tobacco/nicotine equivalent, in her lifetime, but who have quit smoking) who have smoked within the last year and/or were former smokers for 10 years
  • Participants who drink more than 14 drinks per week (more than 2 drinks per night)
  • Participants who use illicit or illegal drugs
  • Participants who are regular users of cannabis substances or substances derived from cannabis such as CBD, CBD oils or balms, cannabis-containing edibles; vaping; smoking; hookahs.
  • NOTE: regular use is defined as long stretches of inhaling or consuming these products over several months or longer. Occasional, but not weekly, use of products with small amounts of CBD-related compounds (e.g. waters with CBD infusions) are not considered regular use.)
  • Participants who are planning a trip to the mountains or to a higher UV index region during the study period
  • Any other medication, condition or disease that in the PI's opinion that may adversely affect the participant's ability to complete the study, substantially impact the study's integrity or may pose a significant risk to the participant
  • Participants who are experiencing perimenopausal or menopausal symptoms
  • Participants who have had a hysterectomy and/or both of their ovaries removed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04356456


Locations
Layout table for location information
United States, New Jersey
Consumer product testing (CPT)
Fairfield, New Jersey, United States, 07004
Sponsors and Collaborators
LycoRed Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Michael Caswell, PhD CPT
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: LycoRed Ltd.
ClinicalTrials.gov Identifier: NCT04356456    
Other Study ID Numbers: LSDH02-001
First Posted: April 22, 2020    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by LycoRed Ltd.:
Nutritional Supplement